Novo Nordisk: New Beacon of Hope Amycretin and Mild U.S. Price Intervention Stop the Plunge

After a year full of setbacks, Novo Nordisk has demonstrated over two trading days that the growth story is not yet over. First, a promising new drug named Amycretin brought fresh optimism, and then the U.S. government eased some pressure on the pricing screws for the blockbusters Ozempic and Wegovy. On Wednesday, the shares of the Danish pharmaceutical company rose nearly 5% during the day in Copenhagen, after they had already responded positively on Tuesday to the encouraging study results for Amycretin. The price is recovering from a massive...